Emerson to deliver continuous manufacturing solution for pharma company

Emerson has partnered with IMA Active on developing new solutions to control continuous manufacturing of oral solid dose pharmaceuticals.

The two companies will focus on making it easier for pharmaceutical manufacturers to adopt continuous manufacturing by improving the quality, quantity and efficiency of production.

In developing the new control strategies, IMA Active, a manufacturer of solid dose processing, will apply its understanding of equipment design, machine integration and process logic to identify optimum performance for essential equipment.

Emerson will couple these new performance strategies with its scalable automation technologies and software to deliver robust process monitoring and control.

Continuous pharmaceutical processes require precise process control, reliable monitoring of critical parameters to assure quality attributes, process analytical technology (PAT) measurements, accurate processing of analytical data, and advanced control techniques.

The new software solution will intelligently detect, predict, and alert the occurrence of adverse production events to improve quality and reduce risk. At the heart of the solution, Emerson’s DeltaV distributed control system will orchestrate the entire oral solid dose continuous manufacturing line, managing control and automation of a wide variety of equipment and subsystems.

“We appreciate partners able to share our holistic vision of automation,”says Marco Minardi, automation manager at IMA Active, in a statement. “Having a powerful and flexible platform to enable predictive analysis, to speed and simplify integration of the Pharma 4.0 ecosystem and with wide data integration capabilities is a requirement.”